Sinopharm, an experimental Covid-19 vaccine, is approved by the UAEs health ministry. MoHAP, Ministry of Health and Prevention, announced the official registration of the Beijing Institute of Biological Product’s Covid-19 vaccine.
MoHAP and the Department of Health Abu Dhabi (DOH) reviewed Sinopharm based on its interim analysis of the phase III trials. The analysis showed that the inactivated vaccine of the Beijing Institute of Biological Product is 86 percent effective against Covid-19.
The analysis also shows “99 percent seroconversion rate of neutralizing antibody. 100 percent effectiveness in preventing moderate and severe cases of the disease”, the ministry said in a statement. Further, the analysis does not show any serious safety issues.
Phase three clinical trials of the vaccine started in July. The UAE approved its use under Emergency Use Authorisation (EUA) program in September.
Administration of volunteers
With a ratio of 2:1 for volunteers to placebo, volunteers were injected with either Vaccine 1 (WIBP), Vaccine 2 (BIBP), or placebo. This process completes with two doses given in 21 days.
Furthermore, in just six weeks, 31,000 volunteers from 125 nationalities participated in the trial.
Emergency Use Authorisation
Sinopharm CNBG, DOH, and G42(an Artificial Intelligence company based in ABU Dhabi) are managing the UAE trials.
For the prevention of frontline workers, MoHAP approved EUA for the vaccine. The UAE is conducting Post Authorisation Safety Study (PASS) and Post Authorisation Efficacy Study (PAES) of its EUA program.
The UAE recorded a total of 178K cases of infection, 160K recovery, and 596 deaths as of December 8.